Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:49 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure
NCT01035255 · Novartis Pharmaceuticals · PHASE3 · terminated · last registry update 2016-08-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Early termination was approved due to compelling efficacy of LCZ696 in patients with HF \& reduced EF after final pre-specified interim analysis 28-Mar-2014.” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AGTR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2017-05-24Phase 3 first posted: Second Xiangya Hospital of Central South University, Jinshuibao Capsule (NCT03164785)
- 2017-03-17Phase 3 first posted: Ludwig-Maximilians - University of Munich, Amlodipine + Losartan (NCT03082014)
- 2017-02-28Phase 3 first posted: Novartis Pharmaceuticals, sacubitril/valsartan + Enalapril (NCT03066804)
- 2017-01-04Phase 3 first posted: Daewoong Pharmaceutical Co. LTD., Amlodipine/Olmesartan 10/40mg (Combination drug), Rosuvastatin 20mg + Olmesartan 40 mg, Rosuvastatin 20mg (NCT03009487)
- 2016-09-26Phase 3 first posted: University of Texas Southwestern Medical Center, Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine) (NCT02913664)
- 2016-09-01Results posted on the registry: Novartis Pharmaceuticals, sacubitril/valsartan (LCZ696) + olmesartan (NCT01870739)
- 2016-04-13Phase 3 first posted: UMC Utrecht, Ceftriaxone + Macrolide + Moxifloxacin or Levofloxacin (NCT02735707)
- 2015-12-17Results posted on the registry: Relypsa, Inc., patiromer + patiromer (NCT01371747)
- 2015-12-03Phase 3 first posted: Boryung Pharmaceutical Co., Ltd, Fimsartan 60mg~120mg + Fimsartan 60mg~120mg (NCT02620306)
- 2015-11-05Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Irbesartan + Placebo (NCT02597361)
- 2015-10-30Results posted on the registry: Tanabe Pharma Corporation, colestilan + candesartan (NCT01976572)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision